Zomedica Corp.: Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity
Zomedica Corp. (OTCQB:ZOMDF) reported record Q2 2026 revenue of $9.5 million, up 37% year over year, with gross margin of 64%. Operating expenses fell 20% to $10.1 million and cash burn improved 38% to $3.4 million. The company said liquidity totaled $44.1 million and cited growth in Diagnostics, Therapeutic Devices, and Development Services.
How this was made
The 30-second read
Why it matters
The company’s Q2 results combine strong YoY revenue growth with reduced operating expenses and improved cash burn, alongside a stated liquidity position, which together can shift near-term risk perception.
Market read
This is a company-specific earnings-style update with quantified revenue, expense, cash burn, and liquidity metrics that can drive trading in Zomedica shares.
What to watch
The release notes lower margins from ramping new products and includes prior-year impairment charges; traders may want to separate underlying operating performance from one-time effects and mix-driven gross margin pressure.
Background
Zomedica is an animal health company focused on point-of-care diagnostics and therapeutic devices, with a newer Development Services segment introduced in late 2025.
Ticker impact
Zomedica reported Q2 revenue of $9.5M, up 37% YoY, with cash burn down to $3.4M and liquidity of $44.1M.
Near-term upside bias if investors reward improved operating leverage and balance-sheet runway; volatility possible given OTC liquidity.
The article provides multiple quantified fundamentals (revenue growth, operating expense decline, cash burn improvement, liquidity level) that directly affect perceived risk and forward expectations.
Market effects
Animal health diagnostics and point-of-care device names may see read-across interest if investors view Zomedica as demonstrating commercial traction and margin discipline.
Limited broader regional impact expected given the company is OTC-listed and the news is company-specific.
International expansion and partnerships are cited, but the disclosure is not large enough to materially move global animal health benchmarks.
Counterpoint
Revenue growth may be partly driven by Development Services and mix shifts, so investors could discount sustainability of margins and cash burn improvements.
Key entities
- companyZomedica Corp.
OTCQB-listed animal health diagnostics and therapeutic devices company reporting Q2 2026 results.
- partnerBoehringer Ingelheim Animal Health
Named collaboration referenced as supporting Diagnostics segment initiatives.
